title: Increased serum immunoreactive parathyroid hormone-related protein levels in chronic hypocalcemia.
abstract: To elucidate possible negative feedback regulation of circulating PTH-related protein (PTHrP) by serum calcium levels, we measured serum immunoreactive PTHrP (iPTHrP) by a specific RIA for PTHrP-(1-34) in patients with hypocalcemia due to PTH deficiency or resistance. Serum iPTHrP levels were not detectable (< 4 pmol/L) in 9 of 11 patients with postoperative hypocalcemia who presented with transient tetany, in 1 patient with hypocalcemia due to hypomagnesemia induced by cisplatin treatment, in normal subjects (n = 60), or in 1 normocalcemic patient with pseudopseudohypoparathyroidism. In contrast, the other 2 patients with postoperative hypocalcemia who had had hypocalcemic symptoms for longer periods (6 months and 3 yr, respectively) showed increased iPTHrP levels (6.3 and 5.3 pmol/L). All 6 patients with idiopathic hypoparathyroidism showed undetectable or low PTH, but increased iPTHrP, ranging from 6.5-19.5 pmol/L (mean +/- SD, 10.8 +/- 4.8 pmol/L). Elevated serum iPTHrP levels (7.4 and 8.1 pmol/L) were also found in both patients with pseudohypoparathyroidism type I. When chronic and profound hypocalcemia in these patients was normalized by treatment with 1 alpha-hydroxyvitamin D3, the elevated serum iPTHrP levels were normalized (undetectable, < 4 pmol/L) in all 6 patients examined. These results suggest that chronic and profound hypocalcemia and/or vitamin D deficiency can stimulate endogenous PTHrP secretion via a negative feedback mechanism, although elevated iPTHrP does not normalize the decreased serum calcium levels.
authors.affiliation: Third Department of Internal Medicine, Gifu University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mune
authors.forename: H
authors.initials: H
authors.lastname: Katakami
authors.forename: M
authors.initials: M
authors.lastname: Morita
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Ushiroda
authors.forename: S
authors.initials: S
authors.lastname: Matsukura
authors.forename: K
authors.initials: K
authors.lastname: Yasuda
authors.forename: K
authors.initials: K
authors.lastname: Miura
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002908:Chronic Disease; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D006996:Hypocalcemia / Q000097:blood*; D007011:Hypoparathyroidism / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D044162:Parathyroid Hormone-Related Protein; D011506:Proteins / Q000032:analysis*; D011863:Radioimmunoassay
chemical_list: D006887:Hydroxycholecalciferols; D009363:Neoplasm Proteins; C470121:PTHLH protein, human; D044162:Parathyroid Hormone-Related Protein; D011506:Proteins; C008088:alfacalcidol